Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

Fast Growing Furious Races for Targeting Fibroblast Growth Factor Receptors

  • Park, Daechan (Department of Molecular Science and Technology, Department of Biological Sciences, Ajou University)
  • Received : 2022.09.17
  • Accepted : 2022.09.26
  • Published : 2022.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Targeting fibroblast growth factor receptors (FGFRs) has been slow compared to other targeted cancer therapies for receptor tyrosine kinases, such as epidermal growth factor receptors. The low efficacy and variable response have limited the growth of FGFR inhibitors in clinical use. Nevertheless, recent systematic and genomic approaches have identified the biological conditions for effectively targeting FGFRs and can accelerate the development of targeted drugs. Under clinical and preclinical trials, the inhibitors started fast growing furious races to target FGFRs. Finally, FGFRs will be more actionable and targetable with more precise and effective drugs at the end of the race, passing the finish line.

Keywords

Acknowledgement

This study was supported by the National Research Foundation, funded by the Ministry of Science and ICT (NRF-2019R1C1C1008181) and the Ministry of Education (NRF-2021R1A6A1A10044950).

References

  1. Ayala-Aguilera, C.C., Valero, T., Lorente-Macias, A., Baillache, D.J., Croke, S., and Unciti-Broceta, A. (2022). Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis. J. Med. Chem. 65, 1047-1131. https://doi.org/10.1021/acs.jmedchem.1c00963
  2. Chan, J.M., Zaidi, S., Love, J.R., Zhao, J.L., Setty, M., Wadosky, K.M., Gopalan, A., Choo, Z.N., Persad, S., Choi, J., et al. (2022). Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180-1191. https://doi.org/10.1126/science.abn0478
  3. Heo, Y.J., Hwa, C., Lee, G.H., Park, J.M., and An, J.Y. (2021). Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol. Cells 44, 433-443. https://doi.org/10.14348/molcells.2021.0042
  4. Katoh, M. (2019). Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105-122. https://doi.org/10.1038/s41571-018-0115-y
  5. Liu, H., Zhang, B., and Sun, Z. (2020). Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun. (Lond.) 40, 43-59. https://doi.org/10.1002/cac2.12005
  6. Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., and Guo, Z. (2022). Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review. Front. Chem. 10, 860985. https://doi.org/10.3389/fchem.2022.860985
  7. Zingg, D., Bhin, J., Yemelyanenko, J., Kas, S.M., Rolfs, F., Lutz, C., Lee, J.K., Klarenbeek, S., Silverman, I.M., Annunziato, S., et al. (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609-617. https://doi.org/10.1038/s41586-022-05066-5